Loading...
| A03705 | Pages: NA | Dec 2021 | 4519 Views | | |
| Author(s) : NA | Tables: NA | Charts: NA |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Norfloxacin Market
Request Now !Norfloxacin is a synthetic broad spectrum antibiotic, which acts against most gram-negative and gram-positive bacteria. This antibiotic is mainly used to treat urinary tract infections by inhibiting bacterial cell division.
The major factors that contribute to the growth of the norfloxacin market include the high prevalence of urinary tract infections (UTI), chronic diseases, and rise in geriatric population contributing to a large patient pool. Moreover, large number of clinical trials and innovative R&D approaches to develop advanced antibiotics drive the market growth. However, development of drug-resistant strains and side effects associated with the use of antibiotic restrain the market growth. The development of prospect molecules and novel combination therapies by R&D processes, which are used to treat antibiotic-resistant microbial infections further provides various opportunities for market growth.
Norfloxacin market is segmented on the basis of brand names, application, and region. Based on brand names, norfloxacin is divided as Chibroxin, Noroxin, and others. On the basis of application, the market is classified into uncomplicated urinary tract infections, complicated urinary tract infections, uncomplicated urethral and cervical gonorrhea, prostatitis, and others, which include pyelonephritis, Salmonella enteric fever, Salmonella gastroenteritis, and shigellosis. By geography, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key players operating in this market include Janssen Pharmaceuticals, Merck KGaA, Eli. Lilly & Co., Bristol-Myers Squibb Company, GlaxoSmithKline plc, AbZ-Pharma GmbH, F. Hoffmann-La Roche AG, Shandong Xinhua Pharmaceutical, Kyorin Pharmaceutical Co., Ltd., and Lancer Health Care Pvt. Ltd.
Key Benefits
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
CHAPTER 4 NORFLOXACIN MARKET, BY BRAND NAMES
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. CHIBROXIN
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. NOROXIN
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.4. OTHERS
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
CHAPTER 5 NORFLOXACIN MARKET, BY APPLICATION
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. UNCOMPLICATED URINARY TRACT INFECTIONS
5.2.1. Market size and forecast
5.3. COMPLICATED URINARY TRACT INFECTIONS
5.3.1. Market size and forecast
5.4. UNCOMPLICATED URETHRAL
5.4.1. Market size and forecast
5.5. CERVICAL GONORRHEA
5.5.1. Market size and forecast
5.6. PROSTATITIS
5.6.1. Market size and forecast
5.7. OTHERS
5.7.1. Market size and forecast
CHAPTER 6 NORFLOXACINMARKET, BY REGION
6.1. OVERVIEW
6.2. NORTH AMERICA
6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast
6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast
6.2.4. North America Norfloxacin Market by Brand Names
6.2.5. North America Norfloxacin Market by Application
6.3. EUROPE
6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast
6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Italy market size and forecast
6.3.3.5. Spain market size and forecast
6.3.3.6. Rest of Europe market size and forecast
6.3.4. Europe Norfloxacin Market by Brand Names
6.3.5. Europe Norfloxacin Market by Application
6.4. ASIA-PACIFIC
6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast
6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. Australia market size and forecast
6.4.3.4. India market size and forecast
6.4.3.5. South Korea market size and forecast
6.4.3.6. Rest of Asia-Pacific market size and forecast
6.4.4. Asia-Pacific Norfloxacin Market by Brand Names
6.4.5. Asia-Pacific Norfloxacin Market by Application
6.5. LAMEA
6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast
6.5.3.1. Brazil market size and forecast
6.5.3.2. Saudi Arabia market size and forecast
6.5.3.3. South Africa market size and forecast
6.5.3.4. Rest of LAMEA market size and forecast
6.5.4. LAMEA Norfloxacin Market by Brand Names
6.5.5. LAMEA Norfloxacin Market by Application
CHAPTER 7 COMPANY PROFILES
7.1. JANSSEN PHARMACEUTICALS
7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments
7.2. MERCK KGAA
7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments
7.3. ELI. LILLY & CO.
7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments
7.4. BRISTOL-MYERS SQUIBB COMPANY
7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments
7.5. GLAXOSMITHKLINE PLC
7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments
7.6. ABZ-PHARMA GMBH
7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments
7.7. F. HOFFMANN-LA ROCHE AG
7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments
7.8. SHANDONG XINHUA PHARMACEUTICAL
7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments
7.9. KYORIN PHARMACEUTICAL CO., LTD.
7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments
7.10. LANCER HEALTH CARE PVT. LTD.
7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments
Clients can easily download both quantitative as well as
qualitative reports in PDF and excel formats.
Start reading.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
10%
Discount
10%
Discount
10%
Discount
10%
Discount
Enterprise
License/PDF
10%
Discount
Buy Now *Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
